Finally, multiple experimental studies in animal models of cirrhosis have reported increased bacterial translocation and indicated that treatment with both natural and synthetic FXR agonists improved intestinal barrier integrity [3–6, 42]. This evidence concerns the gene NR1H4 and Cirrhosis.